RheumNow Live 2026

• Target Audience: rheumatologists and immunologists
• Sample video: contact me for sample video
• Information:

1. Overview

RheumNow Live 2026 provides a comprehensive and cutting-edge clinical update on rheumatology and autoimmune diseases. The program features expert insights into the diagnosis, management, and emerging therapies for conditions such as rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and gout, along with specialized updates on vasculitis, osteoporosis, and osteoarthritis.

2. Learning Objectives

Evaluate recent advances in the diagnosis and management of rheumatoid arthritis, including interstitial lung disease (ILD) complications and the mucosal hypothesis.

Analyze the evolving treatment landscapes for systemic autoimmune conditions such as large and small vessel vasculitis and Sjögren’s syndrome.

Assess the impact of patient comorbidities, including obesity and inflammation, and apply risk mitigation strategies for rheumatic patients undergoing orthopedic surgery.

Identify emerging therapeutic options and mechanisms of action presented in clinical showcases for advanced rheumatic disease management.

3. Target Audience

Best for rheumatologists and immunologists who want updates on rheumatoid arthritis, spondyloarthritis, and emerging autoimmune therapies.

4. Topics

2026 Advances in Spondyloarthritis

Advancing Practice Faculty QA

Asymptomatic Elevation of CK

Autoimmune Faculty QA

Closing Comments Adjourn

Diagnosing Axial Spondyloarthritis in 2026

Disease Modification in Osteoarthritis

Embracing Relapses in PMR and GCA

Helicobacter Pylori Update

Highlights in Autoimmune Disease

History of Gout

ILD in RA – Recent Advances

Large Small Vessel Vasculitis

Mitigating Risk for Rheumatic Disease Patients Undergoing Orthopedic Surgery

Mortality in Rheumatoid Arthritis A Story of Decline Delay or Plateau

Obesity and Inflammation Weight Management in Rheumatology

Osteoporosis A 50 Year Journey

Paradoxical Psoriasis and Strange Reactions

Past Present Future of Gout

Placebos in Rheumatology

Pod 1 Rheumatoid Arthritis Achieving Better Outcomes

POD 2 Advancing Practice

POD 3 Decisions in Psoriatic Arthritis

Post-Reception Performance

Psoriatic Arthritis Faculty QA

Rheumatoid Arthritis Faculty QA

Sjogrens Treatment Landscape in 2026

Small Vessel Vasculitis

SMILE Study – Hydroxychloroquine in ANA Arthralgia

Spondyloarthritis Complications

Spondyloarthritis Faculty QA

Staying Ahead of Spondyloarthritis

The Mucosal Hypothesis of Rheumatoid Arthritis

Update on Myositis Antibodies

Vasculitis Faculty QA

VIRTUAL SHOWCASE AMGEN

VIRTUAL SHOWCASE Eli Lilly

VIRTUAL SHOWCASE Genentech

VIRTUAL SHOWCASE Sanofi

Welcome Introduction 2

Welcome Introduction

Why Do Plain Xrays in Psoriatic Arthritis